A post-marketing active surveillance of insulin human inhalational powder in adult patients with diabetes mellitus

Diabetes as a metabolic disease has reached epidemic proportions in India. Inhaled insulin is one of the promising non-invasive candidates to address concerns with current treatment options. This is an open label, prospective, non-comparative, multicentre, post-marketing active surveillance in diabetes mellitus on the use of inhaled insulin for 6 months. Patients who are prescribed Afrezza*®* (Insulin human Inhalational Powder) as per prescribing information will be enrolled as per eligibility criteria in this surveillance. Safety and tolerability will be evaluated by recording adverse events during follow-up period of 6 months from the available data.